A healthcare-services deal built around where complex drugs are delivered
Option Care Health became one of the largest U.S. stock movers on October 6 after McKesson and private-equity firm CD&R agreed to acquire the home-infusion provider in a transaction valued at approximately $5.8 billion including debt.
The offer price is $32.05 per share, about a 37% premium to Option Care’s October 5 closing price. OPCH shares jumped more than 30% after the announcement, moving close to the deal price.
The size of the premium is notable, but the strategic logic matters more. Specialty drugs, biologics and treatments for rare or complex conditions are becoming a larger part of U.S. pharmaceutical spending. Many of those therapies need infusions, monitoring and specialized handling. Delivering them in hospitals can be expensive. Home and ambulatory infusion can lower the site-of-care cost while improving convenience for suitable patients.
That makes Option Care less like a traditional pharmacy and more like healthcare infrastructure.
How the transaction is structured
CD&R will own approximately 51% of Option Care at closing, while McKesson will invest roughly $1.4 billion for a 49% minority stake. Option Care will remain a separate company with its own management team.
The agreement also creates a framework that could allow McKesson to acquire CD&R’s interest later, subject to specified conditions and regulatory approvals. That gives McKesson strategic exposure today without taking full ownership immediately.
The transaction is expected to close in the first half of calendar 2027, pending Option Care shareholder approval, regulatory clearance and customary closing conditions.
The structure is important. McKesson is not simply buying a distributor. It is investing alongside a financial sponsor in a provider network that sits closer to the patient. That can expand McKesson’s role across the specialty-therapy value chain.
Why home infusion is becoming more valuable
The U.S. healthcare system has been pushing appropriate care out of hospitals for years because hospital settings are expensive. The economics become even more important as specialty therapies grow.
Infusion drugs can require refrigeration, sterile preparation, clinical monitoring, insurance authorization and precise scheduling. A scaled provider can coordinate these steps across patients, physicians, payers and pharmaceutical manufacturers.
Option Care is the largest independent infusion provider in the United States, serving more than 300,000 patients annually through a national network of home and ambulatory sites. Scale matters because payers and drug manufacturers prefer partners that can manage complex therapies consistently across geographies.
For McKesson, this creates a bridge between pharmaceutical distribution and care delivery. McKesson already has major relationships with manufacturers, oncology practices and specialty-care providers. Option Care adds a national last-mile clinical network for administering therapies closer to home.
Market impact: why investors paid attention to the premium
A roughly 37% premium suggests buyers were willing to pay for strategic scarcity. Large national home-infusion networks are difficult to replicate because they require clinical staff, payer contracts, pharmacy capabilities, logistics and local operating infrastructure.
That premium can also become a valuation reference for other healthcare-services companies exposed to alternate sites of care, specialty pharmacy or home-based treatment.
The transaction supports a wider theme in healthcare investing: the highest-value assets are often not the drug manufacturers themselves but the networks that control patient access, reimbursement and delivery.
McKesson’s role is especially interesting because large drug distributors are trying to move beyond low-margin physical distribution into higher-value services. Specialty care offers more durable growth because the therapies are expensive, clinically complex and often require ongoing support.
The debate: lower-cost care versus concentration and reimbursement risk
The bullish case is that home infusion is aligned with nearly every major healthcare cost trend. Payers want lower-cost sites of care. Patients often prefer treatment at home when clinically appropriate. Biopharma companies need reliable networks to deliver complex drugs. Providers want to avoid unnecessary hospital capacity usage.
The skeptical case starts with reimbursement. Home infusion economics depend on contracts with commercial insurers, government programs and health systems. Pricing pressure can rise if payers become more aggressive or if reimbursement rules change.
Labor is another risk. Infusion therapy requires nurses, pharmacists and specialized staff. A shortage of clinicians can limit capacity and raise costs even when patient demand is strong.
Drug-mix risk also matters. New therapies can create growth, but the economics differ by indication and payer. A provider can gain volume without gaining equivalent profit if reimbursement fails to cover the full operating burden.
There is also execution risk in the ownership structure. McKesson and CD&R need to support growth without creating conflicting priorities between strategic and financial objectives.
Why McKesson may prefer the staged ownership model
The 49% stake allows McKesson to participate in earnings through the equity method while limiting the immediate balance-sheet commitment relative to a full acquisition. It also gives the company time to evaluate how Option Care performs inside a deeper specialty-care partnership.
If the platform grows as expected, the framework to acquire CD&R’s interest later can become valuable. If industry economics weaken, McKesson has not paid the full enterprise value up front.
The structure also leaves Option Care’s management in place, which can reduce disruption to payer relationships, clinical operations and employees.
For shareholders, the key question is whether this model creates more strategic value than a conventional acquisition. The answer will depend on how effectively McKesson can direct specialty-pharma relationships and product flow through Option Care’s network.
Risks and what to watch before closing
The first milestone is Option Care shareholder approval. The second is regulatory review. Because the buyers operate in healthcare distribution and investment markets rather than as a direct home-infusion competitor of identical scale, the antitrust framework is different from a horizontal provider merger, but regulators will still examine competitive effects.
Investors should also watch for any changes in the expected first-half 2027 closing schedule, financing conditions or ownership terms.
For McKesson, future disclosures around specialty-care revenue, earnings contribution from the 49% stake and any progress toward acquiring the remaining interest will be critical.
For the broader healthcare-services sector, watch for follow-on transactions. A premium this large can encourage other strategic buyers and private-equity firms to revisit assets in home health, specialty pharmacy and alternate-site care.
Conclusion
The Option Care transaction is a bet on the migration of complex medicine away from the hospital and toward lower-cost community settings. McKesson is positioning itself not only as a distributor of specialty drugs but as a strategic participant in the network that administers them.
The $32.05-per-share offer and $5.8 billion enterprise value show how valuable national infusion infrastructure has become. The long-term investment question is whether home infusion can keep expanding while maintaining reimbursement, labor availability and clinical quality. If it can, Option Care may prove to be an early example of a much larger consolidation cycle around where high-cost therapies are actually delivered.